Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Rutgers Cancer Institute’s Dr. Richard Drachtman Tapped for National Cancer Institute Board

New Brunswick, NJ, March 13, 2014 — Richard Drachtman, MD, interim chief of pediatric hematology/oncology at Rutgers Cancer Institute of New Jersey has been appointed as Vice Chair of the National Cancer Institute (NCI) Pediatric Central Institutional Review Board (PedCIRB).

Dr. Drachtman, who also is a professor of pediatrics at Rutgers Robert Wood Johnson Medical School, was selected based on his experience as an NCI PedCIRB member, having served on the panel since 2009.  He also was selected based on his knowledge of current clinical oncology practice and experience working with NCI Cooperative Groups.

The PedCIRB reviews NCI-sponsored pediatric clinical trials conducted by the world’s largest pediatric cancer research entity known as the Children’s Oncology Group. 

The PedCIRB was created in 2004 as a means to further increase patient protection by assembling a group of pediatric cancer experts to review clinical trials before they are offered to patients.  The expert panel includes pediatric oncologists, nurses, childhood cancer survivors and consumer advocates.

In addition to being the author of numerous articles, editorials and reviews, Drachtman — who is widely recognized for his clinical expertise and research in childhood cancer and sickle cell disease — also has edited and authored books and book chapters relating to the field.